- CEO
- Jing Zhang
- Full Time Employees
- 1,881
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Shaerqin Industrial Park Hohhot MO China 010111
- IPO Date
- Jan 15, 1999
- Business
- Jinyu Bio-Technology Co., Ltd. (600201.SS) engages primarily in the research, development, production, and sale of veterinary biological products in China. The company offers a comprehensive portfolio of over 110 animal vaccines and diagnostic products covering swine, ruminant, avian, and companion animals; key offerings include foot-and-mouth disease (FMD) vaccines, where it ranks as China's top producer and supplier with 10 billion mL produced in the past decade, porcine vaccines such as those for mycoplasma pneumoniae, porcine reproductive and respiratory syndrome, and pseudorabies, ruminant vaccines for brucellosis, bovine viral diarrhea, and mucosal disease, avian vaccines, pet vaccines including rabies, and diagnostic reagents. It operates through five subsidiaries focused on the animal health industry, supported by three Chinese national laboratories and advanced manufacturing at the Jinyu Bio-Technology Industrial Park in Inner Mongolia, which features seven intelligent vaccine production lines and two diagnostic reagent lines introduced in 2019. Founded in 1993 and listed on the Shanghai Stock Exchange in 1999, Jinyu Bio-Technology is headquartered at No. 1 Jinyu Street, Shaerqin Industrial Park, Hohhot, Inner Mongolia, China, with approximately 1,740 employees; it also conducts ancillary activities in textile processing, property leasing and management, and energy products. Recent developments include a recovery in core product sales and overall operations as of the first three quarters of 2025, with revenue reaching RMB 1.042 billion, up 7.38% year-over-year, alongside obtaining a new veterinary drug registration certificate for a gene-engineered subunit vaccine against Clostridium perfringens (Type A) in cattle and cumulative share repurchases representing 1.4134% of outstanding shares.